Biotest GmbH KGaA (HMSE:BIO0) After Trimodulin Buzz Faces A Split Valuation View
Biotest GmbH KGaA (HMSE:BIO0) is back in focus after fresh industry commentary highlighted its Trimodulin candidate among emerging therapies in community-acquired bacterial pneumonia, drawing attention to the company’s role in this specific treatment niche.
Set against the Trimodulin headlines, Biotest GmbH KGaA’s share price sits at €33.2 with a 90‑day share price return of 3.11% and year to date gain of 5.06%, while the 12.30% total shareholder return over one year points to gradually improving momentum.
Scan beyond Biotest GmbH KGaA and find other plasma and specialty pharma players that may be primed for the next move with our curated 617 high quality undiscovered gems.
Bears point to Biotest GmbH KGaA’s loss-making profile, and bulls to Trimodulin’s spotlight and a €1.31b valuation. Which side does the current evidence support as the valuation numbers come into focus?
Preferred Price-to-Sales Multiple of 2x: Is it justified?
Biotest GmbH KGaA trades on a P/S ratio of 2x, while the share price is €33.2 and the business carries a market value of about €1.31b.
The price-to-sales multiple compares the equity value of Biotest GmbH KGaA to its €648.9m in revenue. For a loss-making plasma and biotech specialist, investors often lean on sales rather than earnings, because net income of a €70.7m loss and a declining Return on Equity of 15.25% do not yet offer a clean profit benchmark.
On that measure, the stock is marked at a sizeable discount to peers. The same P/S ratio of 2x compares to 6.2x for its direct peer group and 9.1x across the wider European biotechs industry. That gap suggests the market is either being cautious about Biotest GmbH KGaA’s funding mix, with 100% of liabilities coming from higher risk borrowing and debt not well covered by operating cash flow, or is yet to credit the product portfolio and Trimodulin partnership with Grifols to the same extent it has done for other listed drug developers.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Sales of 2x (UNDERVALUED)
Still, the loss of €70.7m and reliance on borrowing for 100% of liabilities leave Biotest GmbH KGaA exposed if funding tightens or the Trimodulin partnership underdelivers.
Find out about the key risks to this Biotest GmbH KGaA narrative.
Another view on Biotest GmbH KGaA’s value
The low P/S ratio hints at opportunity, yet our DCF model points the other way. Based on estimated future cash flows, Biotest GmbH KGaA screens as overvalued, with the current €33.2 price compared with an implied value of about €1.19. Which lens belongs at the top of your checklist?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Biotest GmbH KGaA for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 252 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Uncertain about whether the Biotest GmbH KGaA story skews bullish or cautious right now. Act while the data is fresh and weigh the 1 important warning sign.
Looking for more investment ideas beyond Biotest GmbH KGaA?
Do not stop with one ticker. Broaden your watchlist now so you keep options open and avoid missing opportunities that better match your risk and return preferences.
- Target potential mispricing and hunt for quality at a discount with the 252 high quality undervalued stocks.
- Build a steadier income stream by focusing on companies in the 169 dividend fortresses.
- Prioritise resilience by screening for companies on the 309 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com